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Edited by Richard MaraisAbstract We investigated the eﬀect of aldosterone on Src
kinase. In the kidney cell line, M-1 aldosterone leads to a >2-
fold transient activation of Src kinase seen as early as 2 min
after aldosterone administration. Maximal Src kinase activation
was measured at an aldosterone concentration of 1 nM. In
parallel to activation, autophosphorylation at Tyr-416 of Src
kinase increased. Src kinase activation was blocked by spirono-
lactone. Aldosterone led to increased association of Src with
HSP84. Furthermore, rapamycin blocked aldosterone-induced
Src activation. We conclude that Src activation by aldosterone is
mediated through the mineralocorticoid receptor and HSP84.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Like all steroid hormones, aldosterone has a dual mecha-
nism of action. It aﬀects the transcriptional modulation of
target genes via the intracellular mineralocorticoid receptor,
but also elicits rapid non-genomic eﬀects on second messenger
systems and signaling cascades similar to those initiated by
peptide hormones or catecholamines (for review see [1]).
However, the signaling cascade and in particular the initiating
step of rapid aldosterone signaling is rather unclear. A large
body of evidence points to a membrane aldosterone receptor
diﬀerent from the mineralocorticoid receptor, since most de-
scribed rapid eﬀects could not be blocked by the MR inhibitor
spironolactone. In the case of other steroid hormones, most
reports indicate that the classical intracellular hormone re-
ceptors are responsible for rapid signaling. Rapid progester-
one, androgen, estrogen and vitamin D signaling starts with
activation of Src kinase, which is achieved by direct interaction
of the steroid–steroid hormone receptor-complex with Src [2–
4]. Whether such a mechanism also applies to rapid aldoste-
rone signaling is so far unknown. The only report dealing with
Src kinase and rapid mineralocorticoid signaling stems from
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dosterone responsive upon transfection with the epidermal
growth factor receptor.
In this study, we wanted to know whether Src kinase is in-
volved in rapid aldosterone signaling in the kidney cell lineM-1.
M-1 cells were chosen, since they serve as a model system for
cortical collecting duct cells which are aldosterone target cells
[6]. There is increasing evidence that aldosterone exerts rapid
eﬀects in the kidney playing a role in modulation of ion channel
and transporter activity and thereby inﬂuencing renal transport
(for review see [7]). In M-1 cells, aldosterone produced a rapid
increase in intracellular Ca2þ concentrations [8]. In a cell line
with properties similar to M-1 cells, Madin–Darby canine
kidney cells (MDCK), Gekle et al. demonstrated rapid activa-
tion of Naþ/Hþ exchange which required Ca2þ and rapid in-
crease of plasma membrane conductance by aldosterone [9] and
that aldosterone uses the EGF-R-ERK1/2 signaling cascade to
elicit its rapid eﬀects in MDCK cells [10]. Furthermore, as al-
ready mentioned proofs exist that Src kinase is involved in al-
dosterone caused EGF-R activation [5], i.e., inhibition of Src
prevented the eﬀect of aldosterone on downstream signaling.
Since aldosterone was shown to induce a left-shift in the dose–
response curve of EGF, which is known to be a highly potent
cellular proliferation factor, not only ion transport, but also cell
proliferation might be modulated by aldosterone.
We show that aldosterone rapidly leads to Src kinase acti-
vation in M-1 cells, analyze the time course and dose–response
of this eﬀect and characterize the mechanism involved by
checking the phosphorylation status of Src, identifying Src-
associated proteins and examining the eﬀect of spironolactone
and rapamycin.2. Materials and methods
2.1. Tissue culture
The M-1 cell line (European Collection of Cell Cultures, Salisbury)
was cultured in a 1:1 mixture of DMEM and Ham’s F-12 medium
(Gibco), supplemented with 10% FCS, 0.5% penicillin/streptomycin
and 2 mM L-glutamine. Before treatment with various substances, cells
were grown to subconﬂuence and serum-starved for 2 h in PSS (135
mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2, 10 mM HE-
PES and 5.5 mM glucose, pH 7.4). Aldosterone (Fluka), 17b-estradiol
(Sigma) or EGF (Sigma) was directly added to PSS and incubated for 5
min when not otherwise indicated. Control treatment was done with
the solvent ethanol (J.T. Baker) for aldosterone and 17b-estradiol, or
with DMEM/F-12 for EGF. For inhibitor treatment, the inhibitors
were directly added to PSS 15 min prior to the addition of aldosterone
(PP2 and PP3, Calbiochem, dissolved in DMSO; spironolactone, Sig-
ma, dissolved in ethanol) or added simultaneously with aldosteroneation of European Biochemical Societies.
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ferent substances added are given in the ﬁgure legends.
2.2. Src kinase immunoprecipitation
Cells were lysed in RIPA buﬀer (50 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% NP40, 1 mM PMSF, 1 mM sodium ortho-
vanadate, 1 mM NaF and 1 Complete Minitablet EDTA free, Boeh-
ringer–Mannheim, per 10 ml) by rotating at 4 C and centrifuged (15
min, 20 800 g, 4 C). Lysates (1 lg/ll) were precleared with 100 ll
protein G agarose (Boehringer–Mannheim)/ml. Supernatants were
incubated with anti-src, clone GD11, agarose (Upstate Biotechnology)
or protein G-agarose at a concentration of 4 lg/150 lg protein lysate
overnight at 4 C. Immunoprecipitates were washed three times with
PBS.
2.3. Identiﬁcation of Src-associated proteins
25 mg lysate obtained from 25 10 cm petri dishes of cells treated
with aldosterone (109 M, 5 min) was, after preclearing, immunopre-
cipitated with 50 lg anti-src, clone GD11, agarose, separated by SDS–
PAGE and stained with Coomassie blue. Bands were excised and
reduced/alkylated by sequential treatment with DTT and iodoaceta-
mide. Proteolysis was performed using modiﬁed trypsin (Promega) at
37 C for 4 h with ﬁnal cleanup on C18 ZipTips (Millipore). The di-
gests were spotted on a stainless steel target in cyanohydroxycinnamic
acid as matrix. Peptide mass spectra were collected on a BiﬂexIII
(Bruker) in the reﬂector mode. Protein identiﬁcation was done with the
Mascot search engine (www.matrixscience.com).
2.4. Western blotting analysis
Immunoprecipitates from 250 lg lysate were separated by 10% SDS–
PAGE and blotted. Western blots were incubated with the following
antibodies: anti-c-src (Santa Cruz), anti-phospho-src (Tyr416), anti-
phospho-src (Tyr527) (Cell Signaling) and anti-HSP84 (Dianova).
Detection was done using Western blotting detection reagent (Amer-
sham).
2.5. Src kinase assay
Immunoprecipitates from 150 lg lysate were washed twice with Src
kinase reaction buﬀer (100 mM Tris–HCl, pH 7.2, 125 mM MgCl2, 25Fig. 1. (A) Eﬀect of aldosterone (109 M) on Src kinase activity. Src was i
noprecipitation was done using protein G agarose. In parallel, Src immunopre
(B) Eﬀect of PP2 and PP3 (107 M) on aldosterone-induced Src kinase activ
activity. P < 0:05, P < 0:01 vs. control.
Fig. 2. (A) Time dependency of aldosterone (109 M)-induced Src kinase a
towards repeated stimulation. Aldosterone was added for 5 min, 2 5 min
P < 0:01 vs. control.mMMnCl2, 2 mM EGTA, 0.25 mM sodium orthovanadate and 2 mM
DTT) and reactions were carried out using the Src Kinase Assay Kit
(UpstateBiotechnology). For inhibitor studies, PP2 orPP3was added to
the immunoprecipitates and incubated 15 min prior to Src kinase assay.
2.6. Data evaluation
Mean values and standard deviations of Src kinase activities were
calculated from at least three independent experiments. Data
were analyzed by an unpaired t-test, one-sampled t-test or ANOVA
where appropriate.
3. Results and discussion
3.1. Src kinase is activated upon treatment of M-1 cells with
aldosterone
M-1 cells, a model system for aldosterone responsive cells of
the cortical collecting duct, were treated with pharmacological
doses of aldosterone. Src kinase was immunoprecipitated from
total cell lysates and assayed for kinase activity (Fig. 1A).
Control treated cells displayed a basal Src activity of 0.37
pmol/min per 150 lg immunoprecipitated lysate. Aldosterone
treatment led to a stimulation of Src kinase activity by a factor
of 2.42 0.69, which was statistically highly signiﬁcant
ðP ¼ 0:003Þ. In cell lysates incubated with protein G, neither
Src kinase was precipitated nor activity was measurable and in
kinase reactions without added speciﬁc substrate negligible
activity was measured. These results indicate the speciﬁcity of
the used anti-Src antibody and the Src kinase activity test.
Further proof that indeed Src kinase activity was measured
came from experiments with the Src kinase inhibitor PP2
(Fig. 1B). When immunoprecipitates from aldosterone stimu-
lated cells were pretreated with PP2 no activation of Src kinase
was measured, whereas in reactions carried out with the un-
active compound PP3 the stimulatory aldosterone eﬀect wasmmunoprecipitated and activity tests were performed. Control immu-
cipitates were analyzed by Western blotting using an anti-Src antibody.
ity. (C) Eﬀect of 17b-estradiol and EGF (both 109 M) on Src kinase
ctivation. (B) Sensitivity of aldosterone-induced Src kinase activation
with a wash out phase of 60 min, and 65 min, respectively. P < 0:05,
Fig. 3. Dose dependency of aldosterone-induced Src kinase activation.
Src was immunoprecipitated, activity tests and Western blotting
analyses were done. Representative Western blots using anti-Src, anti-
Src (P-Tyr416) and anti-Src (P-Tyr527) antibodies are shown. The
signals of the anti-Src (P-Tyr416) Western blot were densitometrically
analyzed and are shown as fold change vs. control.
Fig. 4. Sensitivity of aldosterone (109 M)-induced Src kinase activa-
tion towards spironolactone (106 M).
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stead of immunoprecipitates were pretreated with PP2 or PP3
prior to aldosterone administration (not shown), i.e., the in-
hibitory eﬀect of PP2 in vitro was also obtained in vivo.
To determine the speciﬁcity of the eﬀect of aldosterone, we
assessed the eﬀect of 17b-estradiol (Fig. 1C). 17b-Estradiol
could not activate Src kinase. On the other hand, EGF, a
growth hormone known to act on cortical collecting duct cells
via tyrosine kinases [11], did cause an activation.
The data are the ﬁrst direct proof that aldosterone leads to Src
kinase activation in a cellular system, known to be responsive to
aldosterone. The approximately 2-fold Src kinase activation
after treatment of cells with 1 nM aldosterone found here is
comparable to what can be achieved by most other steroid
hormones, however, at a 10 times higher concentration [2,3].
3.2. Time dependence of aldosterone-induced Src kinase
activation
Signiﬁcant changes of Src kinase activity were obtained
upon addition of aldosterone over the range of 2–60 min
(overall P ¼ 0:0068, ANOVA). The result is consistent with a
non-genomic activation of Src by aldosterone. Although we
did not test whether inhibitors of transcription or translation
aﬀect the aldosterone stimulated Src activation, the rapidity of
the activation, seen already 2 min after aldosterone adminis-
tration, excludes a genomic mechanism. The activation is only
transient, as seen similarly for other rapid steroid hormone
eﬀects as well [12]. However, when aldosterone was washed out
after administration of 5 min and applied a second time after a
60-min recovery period, cells become again sensitive (Fig. 2B).
3.3. Aldosterone leads to Src activation in a dose-dependent
manner by increasing its autophosphorylation
The aldosterone eﬀect on Src kinase activity was dose-de-
pendent (Fig. 3). It was maximal at an aldosterone concen-
tration of 109 M (2.56-fold 0.74). Higher concentrations led
to the same or slightly reduced increase in Src kinase activity
(Fig. 3). The dose dependency of the aldosterone-induced ra-
pid Src kinase activation is similar to dose dependency of other
rapid aldosterone eﬀects [13] and the half maximal eﬀect oc-
curred at physiological aldosterone concentrations of 0.1–1 M
aldosterone [14].
We further analyzed the phosphorylation state of Src at the
two tyrosine residues at positions 416 and 527. Phosphoryla-
tion at Tyr-416 is required for enzymatic activity. Phosphory-
lation at Tyr-527 causes adoption of an inactive conformation
[15]. Src phosphorylated at Tyr-416 increased in parallel to the
activity with increasing aldosterone concentrations, whereas
the phosphorylation status of Tyr-527 did virtually not change
(Fig. 2B). Hence, Src activated by aldosterone treatment is
phosphorylated at both tyrosine residues, Tyr-416 and Tyr-527.
According to the model of Src activation developed by Superti-
Furga [15], association of Src with other proteins overcomes the
inactive conformation despite a phosphorylated Tyr-527. Our
results indicate therefore that aldosterone induces phosphory-
lation of Tyr-416 and association of Src with other proteins,
resulting in an active Src kinase.
3.4. Aldosterone-induced Src kinase activation is consistent with
mineralocorticoid receptor participation
Next, we asked the question whether it is a direct interaction
between Src kinase and the mineralocorticoid receptor whichleads to Src activation as it is known for the androgen, es-
trogen and progesterone receptor. However, in Src immuno-
precipitates of cells treated with aldosterone, no MR was
detectable using Western blotting analysis and a MR speciﬁc
antibody (not shown). This does not necessarily mean that MR
is not involved. Therefore, we tried a second approach, namely
treatment of cells with the MR antagonist spironolactone.
Spironolactone prevented the aldosterone-induced Src kinase
activation completely (Fig. 4).
For most rapid aldosterone eﬀects described so far the in-
volvement of the classical mineralocorticoid receptor could be
ruled out, since spironolactone did not block these eﬀects. Yet,
in a few publications sensitivity of rapid aldosterone eﬀects
towards spironolactone is reported [16,17]. Apparently, there
seem to be at least two diﬀerent pathways for rapid aldoste-
rone action as identiﬁed by the eﬀect of sensitivity towards
spironolactone. This is not uncommon if compared with other
steroids; e.g., estrogens have been demonstrated to expose
rapid actions which are mostly sensitive to the ‘‘classic’’ in-
hibitor ICI 182,780. Some reports on rapid actions fail to
demonstrate that sensitivity, however [18].
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treatment
In order to elucidate the mechanism by which aldosterone
leads to Src kinase activation, we analyzed Src-associated
proteins in Src immunoprecipitates by MALDI-MS. Among
the identiﬁed proteins was HSP84, the mouse homolog of
human heat shock protein 90b. HSP84 was identiﬁed with a
Mowse score of 76 (signiﬁcance limit¼ 62) and 15% sequence
coverage. The mean error in mass accuracy was 34 ppm. The
apparent molecular weight observed in SDS–PAGE corre-
sponded to the calculated mass. The identity of the protein
band was further conﬁrmed using anti-HSP84 antibody.
Association between Src and HSP84 increased upon treat-
ment of cells with aldosterone; no increase was seen when cells
were preincubated with spironolactone, indicating the in-
volvement of the mineralocorticoid receptor in aldosterone-
induced HSP84–Src association (Fig. 5A).
Heat shock proteins are found in mineralocorticoid receptor
complexes and are released upon aldosterone binding [19].
Since we see that more HSP84 bound to Src shortly after al-
dosterone administration, our results are compatible with a
mechanism for rapid aldosterone action that includes aldo-
sterone-induced release of HSP84 from the aldosterone–min-
eralocorticoid receptor complex and subsequent association of
HSP84 with Src kinase. Such an involvement of HSP release in
rapid aldosterone action was also suggested by Tumlin et al.
[20] for non-genomic aldosterone-induced calcineurin activa-
tion. Similarly, Uhrenholt et al. [16] concluded that aldoste-
rone rapidly inhibits vasoconstriction in renal aﬀerent
arterioles by a mechanism initiated by the mineralocorticoid
receptor and involving HSP90.
To further corroborate our theory, we treated cells with
rapamycin. Rapamycin stabilizes HSP–steroid receptor com-
plexes, slowing the release of HSPs after steroid binding [21].
Consequently, in the presence of rapamycin we would not
expect increased HSP84–Src association after administration
of aldosterone. This is what we saw: in the presence of rapa-
mycin, aldosterone did not lead to an increased HSP84–Src
association. In addition, aldosterone-induced Src kinase acti-
vation was prevented by rapamycin (Fig. 5B).
Taking the results together, aldosterone seems to utilize a
mechanism of Src activation diﬀerent from the one of other
steroid hormone receptors. In contrast to, e.g., androgen,
estrogen and progesterone receptor, the mineralocorticoid
receptor does obviously not directly bind to Src, but exerts itsFig. 5. A) HSP84–Src association after aldosterone (109 M, 5 min)
and spironolactone (106 M, 20 min preincubation) treatment of M-1
cells. Anti-src immunoprecipitates were analyzed by Western blotting
using anti-src and anti-HSP84 antibodies. (B) Eﬀect of rapamycin (12
lM) on HSP84–Src association and Src activation in the absence and
presence of aldosterone (109 M, 5 min).stimulatory eﬀect likely via heat shock proteins which are
released upon aldosterone binding. Both, strong positive ef-
fects of HSP90 on v-src activity [22] as well as inhibition [23],
have been reported in in vitro studies, whereas other enzymes
such as eNOS and protein kinase Akt/PKB are activated by
interaction with HSP90 [24]. In our system, Src kinase activity
is obviously stimulated by HSP association. Additional
studies are necessary to further elucidate the mechanism of
HSP-mediated Src activation by aldosterone and the physio-
logical consequences. However, from our study here and
studies from Krug et al. [5] and Gekle et al. [10], it seems very
likely that in kidney cells Src kinase is one of the most up-
stream targets of rapid aldosterone signaling, which via a
network of downstream targets ﬁnally leads to activation of
Naþ/Hþ exchange.References
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